Scinai Immunotherapeutics (SCNI) Competitors $2.20 -0.07 (-3.08%) Closing price 03:03 PM EasternExtended Trading$2.24 +0.04 (+1.82%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SCNI vs. APRE, ADXN, TRAW, TSBX, ORGS, NLSP, GTBP, JBIO, CLDI, and INDPShould you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Aprea Therapeutics (APRE), Addex Therapeutics (ADXN), Traws Pharma (TRAW), Turnstone Biologics (TSBX), Orgenesis (ORGS), NLS Pharmaceutics (NLSP), GT Biopharma (GTBP), Jade Biosciences (JBIO), Calidi Biotherapeutics (CLDI), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Scinai Immunotherapeutics vs. Its Competitors Aprea Therapeutics Addex Therapeutics Traws Pharma Turnstone Biologics Orgenesis NLS Pharmaceutics GT Biopharma Jade Biosciences Calidi Biotherapeutics Indaptus Therapeutics Aprea Therapeutics (NASDAQ:APRE) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment. Do analysts prefer APRE or SCNI? Aprea Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 785.71%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aprea Therapeutics is more favorable than Scinai Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Scinai Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in APRE or SCNI? 34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 13.6% of Aprea Therapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable valuation and earnings, APRE or SCNI? Scinai Immunotherapeutics has lower revenue, but higher earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAprea Therapeutics$1.50M6.45-$12.96M-$2.37-0.74Scinai Immunotherapeutics$660K3.33$4.80M-$9.57-0.23 Does the media prefer APRE or SCNI? In the previous week, Aprea Therapeutics had 2 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 2 mentions for Aprea Therapeutics and 0 mentions for Scinai Immunotherapeutics. Aprea Therapeutics' average media sentiment score of 0.21 beat Scinai Immunotherapeutics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aprea Therapeutics Neutral Scinai Immunotherapeutics Neutral Which has more risk & volatility, APRE or SCNI? Aprea Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Is APRE or SCNI more profitable? Scinai Immunotherapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Scinai Immunotherapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aprea Therapeutics-1,095.02% -68.39% -55.74% Scinai Immunotherapeutics N/A N/A -40.60% SummaryAprea Therapeutics and Scinai Immunotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Scinai Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCNI vs. The Competition Export to ExcelMetricScinai ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.27M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.2321.4227.3820.03Price / Sales3.33285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book0.437.518.085.67Net Income$4.80M-$55.05M$3.16B$248.47M7 Day Performance-10.93%3.16%2.12%2.90%1 Month Performance-8.14%5.92%4.43%5.75%1 Year Performance-28.80%5.82%35.62%21.36% Scinai Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCNIScinai ImmunotherapeuticsN/A$2.20-3.1%N/A-23.8%$2.27M$660K-0.2320APREAprea Therapeutics3.4832 of 5 stars$1.63+1.6%$15.50+853.8%-55.3%$8.85M$1.50M-0.697ADXNAddex Therapeutics2.733 of 5 stars$8.68+5.7%$30.00+245.6%+22.1%$8.70M$460K-25.5330TRAWTraws PharmaN/A$1.53-1.3%N/AN/A$8.62M$230K-0.0517News CoverageNegative NewsTSBXTurnstone Biologics1.6914 of 5 stars$0.38+3.1%$0.45+18.5%-84.4%$8.52M$19.31M-0.1482ORGSOrgenesis1.8796 of 5 stars$1.75+0.3%N/AN/A$8.40M$662K0.00150Gap UpNLSPNLS PharmaceuticsN/A$2.27-2.6%N/A+1,185.0%$8.38MN/A0.006GTBPGT Biopharma1.4406 of 5 stars$3.32+3.4%$11.00+231.3%+7.6%$8.30MN/A-0.588JBIOJade Biosciences2.6946 of 5 stars$10.48+6.2%$14.00+33.6%N/A$8.30MN/A0.0020News CoverageCLDICalidi Biotherapeutics0.2329 of 5 stars$0.26-8.7%$10.00+3,744.7%N/A$8.27M$50K0.0038High Trading VolumeINDPIndaptus Therapeutics3.3996 of 5 stars$0.45-9.9%$8.50+1,787.2%-81.5%$8.02MN/A-0.306Gap UpHigh Trading Volume Related Companies and Tools Related Companies Aprea Therapeutics Alternatives Addex Therapeutics Alternatives Traws Pharma Alternatives Turnstone Biologics Alternatives Orgenesis Alternatives NLS Pharmaceutics Alternatives GT Biopharma Alternatives Jade Biosciences Alternatives Calidi Biotherapeutics Alternatives Indaptus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCNI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
